$5.34
0.428.54%
At Close: -
$5.13
-0.21-3.93%
After Hours: 4:45 PM EDT
15 minutes delayed
Comments
Loading...
Macrogenics
MGNXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Macrogenics (NASDAQ:MGNX) Stock, Analyst Ratings, Price Targets, Forecasts
Macrogenics Inc has a consensus price target of $14.91 based on the ratings of 14 analysts. The high is $40 issued by SMBC Nikko on February 4, 2022. The low is $4 issued by HC Wainwright & Co. on May 13, 2024. The 3 most-recent analyst ratings were released by BTIG, HC Wainwright & Co., and Barclays on May 24, 2024, May 13, 2024, and May 10, 2024, respectively. With an average price target of $9 between BTIG, HC Wainwright & Co., and Barclays, there's an implied 75.44% upside for Macrogenics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BTIG
HC Wainwright & Co.
Barclays
JMP Securities
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Macrogenics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/24/2024 | Buy Now | 75.44% | BTIG | Kaveri Pohlman | $24 → $9 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | -22.03% | HC Wainwright & Co. | Robert Burns | $16 → $4 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 172.9% | Barclays | Peter Lawson | $25 → $14 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 211.89% | JMP Securities | Silvan Tuerkcan | $22 → $16 | Maintains | Market Outperform | Get Alert |
| 05/10/2024 | Buy Now | 55.95% | BMO Capital | Etzer Darout | $24 → $8 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/10/2024 | Buy Now | — | TD Cowen | Boris Peaker | — | Downgrade | Buy → Hold | Get Alert |
| 05/10/2024 | Buy Now | 36.45% | Stifel | Stephen Willey | $29 → $7 | Downgrade | Buy → Hold | Get Alert |
| 04/09/2024 | Buy Now | — | TD Cowen | Boris Peaker | — | Upgrade | Hold → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan | — | Reiterates | → Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | 387.33% | Citigroup | Yigal Nochomovitz | $13 → $25 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 328.85% | JMP Securities | Silvan Tuerkcan | $16 → $22 | Maintains | Outperform | Get Alert |
| 03/11/2024 | Buy Now | 211.89% | HC Wainwright & Co. | Robert Burns | $14 → $16 | Maintains | Neutral | Get Alert |
| 03/08/2024 | Buy Now | 367.84% | BMO Capital | Etzer Darout | $18 → $24 | Maintains | Outperform | Get Alert |
| 03/08/2024 | Buy Now | 465.3% | Stifel | Stephen Willey | $17 → $29 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 387.33% | Barclays | Peter Lawson | $23 → $25 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | 367.84% | BTIG | Kaveri Pohlman | $12 → $24 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 348.34% | Barclays | Peter Lawson | $12 → $23 | Maintains | Overweight | Get Alert |
| 02/14/2024 | Buy Now | 172.9% | HC Wainwright & Co. | Robert Burns | $12 → $14 | Downgrade | Buy → Neutral | Get Alert |
| 01/24/2024 | Buy Now | 211.89% | JMP Securities | Silvan Tuerkcan | $10 → $16 | Maintains | Market Outperform | Get Alert |
| 12/20/2023 | Buy Now | 153.41% | Citigroup | Yigal Nochomovitz | $7 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 11/27/2023 | Buy Now | 231.38% | Stifel | Jonathan Block | → $17 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | Buy Now | 133.92% | HC Wainwright & Co. | Robert Burns | $14 → $12 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 133.92% | Guggenheim | Charles Zhu | → $12 | Upgrade | Neutral → Buy | Get Alert |
| 08/10/2023 | Buy Now | 172.9% | HC Wainwright & Co. | Robert Burns | → $14 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 94.93% | JMP Securities | Silvan Tuerkcan | $8 → $10 | Maintains | Market Outperform | Get Alert |
| 04/03/2023 | Buy Now | 172.9% | HC Wainwright & Co. | Robert Burns | → $14 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | 133.92% | BTIG | Kaveri Pohlman | $6 → $12 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | 172.9% | HC Wainwright & Co. | Robert Burns | $12 → $14 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | — | Guggenheim | Charles Zhu | — | Downgrade | Buy → Neutral | Get Alert |
| 03/16/2023 | Buy Now | 55.95% | JMP Securities | Silvan Tuerkcan | → $8 | Reiterates | → Market Outperform | Get Alert |
| 01/19/2023 | Buy Now | 55.95% | JMP Securities | Silvan Tuerkcan | $18 → $8 | Maintains | Market Outperform | Get Alert |
| 11/23/2022 | Buy Now | 36.45% | Citigroup | Yigal Nochomovitz | $16 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 11/23/2022 | Buy Now | 133.92% | Guggenheim | Charles Zhu | → $12 | Upgrade | Neutral → Buy | Get Alert |
| 11/22/2022 | Buy Now | — | Cowen & Co. | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/14/2022 | Buy Now | 211.89% | BMO Capital | Etzer Darout | $5.7 → $16 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/07/2022 | Buy Now | 133.92% | HC Wainwright & Co. | Robert Burns | $11 → $12 | Maintains | Buy | Get Alert |
| 10/18/2022 | Buy Now | 114.42% | HC Wainwright & Co. | Robert Burns | $10 → $11 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | 94.93% | HC Wainwright & Co. | Robert Burns | $35 → $10 | Maintains | Buy | Get Alert |
| 08/29/2022 | Buy Now | 211.89% | Citigroup | Yigal Nochomovitz | $13 → $16 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 133.92% | SVB Leerink | Jonathan Chang | $15 → $12 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 55.95% | Barclays | Peter Lawson | $18 → $8 | Maintains | Overweight | Get Alert |
| 07/12/2022 | Buy Now | 289.86% | JMP Securities | Silvan Tuerkcan | $24 → $20 | Maintains | Market Outperform | Get Alert |
| 07/12/2022 | Buy Now | -22.03% | BMO Capital | Etzer Darout | $31 → $4 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/11/2022 | Buy Now | -22.03% | BMO Capital | Etzer Darout | $31 → $4 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/05/2022 | Buy Now | — | Guggenheim | Charles Zhou | — | Downgrade | Buy → Neutral | Get Alert |
| 05/04/2022 | Buy Now | — | Guggenheim | Charles Zhu | — | Downgrade | Buy → Neutral | Get Alert |
| 05/04/2022 | Buy Now | 582.26% | HC Wainwright & Co. | Robert Burns | $41 → $35 | Maintains | Buy | Get Alert |
| 05/04/2022 | Buy Now | 192.4% | SVB Leerink | Jonathan Chang | $23 → $15 | Maintains | Outperform | Get Alert |
| 02/28/2022 | Buy Now | 309.36% | Citigroup | Yigal Nochomovitz | $23 → $21 | Upgrade | Neutral → Buy | Get Alert |
| 02/25/2022 | Buy Now | 348.34% | SVB Leerink | Jonathan Chang | $40 → $23 | Maintains | Outperform | Get Alert |
| 02/11/2022 | Buy Now | 504.29% | BMO Capital | Etzer Darout | → $31 | Initiates | → Outperform | Get Alert |
| 02/04/2022 | Buy Now | 679.73% | SMBC Nikko | David Dai | → $40 | Initiates | → Outperform | Get Alert |
| 11/03/2021 | Buy Now | 640.74% | JMP Securities | Silvan Tuerkcan | — | Maintains | Market Outperform | Get Alert |
| 10/19/2021 | Buy Now | 660.23% | JMP Securities | Silvan Tuerkcan | — | Initiates | → Market Outperform | Get Alert |
FAQ
What is the target price for Macrogenics (MGNX) stock?
The latest price target for Macrogenics (NASDAQ:MGNX) was reported by BTIG on May 24, 2024. The analyst firm set a price target for $9.00 expecting MGNX to rise to within 12 months (a possible 75.44% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Macrogenics (MGNX)?
The latest analyst rating for Macrogenics (NASDAQ:MGNX) was provided by BTIG, and Macrogenics maintained their buy rating.
When was the last upgrade for Macrogenics (MGNX)?
The last upgrade for Macrogenics Inc happened on April 9, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Macrogenics Inc.
When was the last downgrade for Macrogenics (MGNX)?
The last downgrade for Macrogenics Inc happened on May 10, 2024 when BMO Capital changed their price target from $24 to $8 for Macrogenics Inc.
When is the next analyst rating going to be posted or updated for Macrogenics (MGNX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Macrogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Macrogenics was filed on May 24, 2024 so you should expect the next rating to be made available sometime around May 24, 2025.
Is the Analyst Rating Macrogenics (MGNX) correct?
While ratings are subjective and will change, the latest Macrogenics (MGNX) rating was a maintained with a price target of $24.00 to $9.00. The current price Macrogenics (MGNX) is trading at is $5.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.